Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MDNA

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MDNA
DateTimeSourceHeadlineSymbolCompany
15/05/202406:29Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:MDNAMedicenna Therapeutics Corporation
15/05/202405:42Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MDNAMedicenna Therapeutics Corporation
14/05/202404:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
01/05/202405:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
27/04/202405:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
26/04/202404:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
23/04/202406:40Edgar (US Regulatory)Form AW - Amendment Withdrawal RequestNASDAQ:MDNAMedicenna Therapeutics Corporation
17/04/202407:05Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MDNAMedicenna Therapeutics Corporation
17/04/202407:05Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:MDNAMedicenna Therapeutics Corporation
17/04/202407:04Edgar (US Regulatory)Form F-10POS - Post-effective amendment to a F-10EF registrationNASDAQ:MDNAMedicenna Therapeutics Corporation
10/04/202404:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
05/04/202405:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
14/02/202423:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
25/01/202408:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
10/01/202402:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
06/01/202401:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
23/12/202306:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
10/11/202300:56GlobeNewswire Inc.Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingNASDAQ:MDNAMedicenna Therapeutics Corporation
09/11/202302:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
06/11/202323:00GlobeNewswire Inc.Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
04/11/202303:00GlobeNewswire Inc.Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
27/10/202322:55GlobeNewswire Inc.Medicenna Announces Nasdaq Delisting and Cutback of Management TeamNASDAQ:MDNAMedicenna Therapeutics Corporation
26/10/202306:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
25/10/202322:00GlobeNewswire Inc.Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsNASDAQ:MDNAMedicenna Therapeutics Corporation
24/10/202322:18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
24/10/202322:15GlobeNewswire Inc.Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
10/10/202323:57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
10/10/202322:07GlobeNewswire Inc.Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerNASDAQ:MDNAMedicenna Therapeutics Corporation
04/10/202308:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
03/10/202322:00GlobeNewswire Inc.Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and ImmunotherapyNASDAQ:MDNAMedicenna Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:MDNA